Phase 2 N=26 Capecitabine in Treating Patients With Metastatic Breast Cancer
Breast Cancer
Primary: Response Rate — 21 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=775 Phase 3 Clinical Study for the Treatment of Cold Sore
Herpes Labialis
Primary: Time to Healing (TTH) of Vesicular Primary Lesion — 7.00; 7.32 Days — p=0.015
N/A N=425 A Retrospective Study Evaluating the Use of Permacol Surgical Implant in the Repair of Abdominal Wall Defects
Abdominal Wall Defects
Primary: Confirmed Hernia Recurrence — 20 participants
N/A N=62 Intelligent Control Approach to Anemia Management
End-Stage Renal Disease
Primary: Percent Hb 10-12 g/dL — 61.9; 72.5 Percent
Phase 2 N=45 Cardiac Hormone Replacement With Brain Natriuretic Peptide (BNP) in Heart Failure
Congestive Heart Failure · Cardiomyopathy
Primary: Change in Left Ventricular (LV) Volume Index at 8 Weeks — -5.2; 5.8; -10.0; 6.1 ml/m^2 — p=0.004
N/A N=50 Agility LP Ankle Arthroplasty Outcomes
Rheumatoid Arthritis of Ankle · Osteoarthritis of Ankle · Traumatic Arthritis of Ankle
Primary: Assessment of Functional Outcomes Following Agility LP Ankle Replacement — 37.67; 37.07 Degrees
Phase 4 N=105 Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma
Carcinoma, Renal Cell
Primary: Progression-free Survival (PFS) — 61.7 Weeks
N/A N=687 Study On Liprimar (Atorvastatin) In Patients With Coronary Heart Disease (CHD) And High Risk Of Cardiovascular Complications
Cardiovascular Diseases · Coronary Artery Disease
Primary: Percentage of Participants Achieving LDL Level Less Than or Equal to (≤) 100 mg/dL at the 6 Month Visit — 51.52 percentage of participants
Phase 2 N=44 18F-FLT-PET in Breast Cancer (MK-0000-139)
Breast Cancer
Primary: Change From Baseline in 18F-FLT-PET Mean Standardized Uptake Value (SUVmean) After the First Cycle of Standard of Care (SOC) Neo-adjuvant Chemotherapy. — 2.79; 1.78…
Phase 2 N=63 Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer
Breast Cancer
Primary: Number of Participants Who Remained Alive Without Evidence of Recurrence as a Measure of Tolerability of Adjuvant Nab Paclitaxel — 63 Participants
Phase 2 N=30 Low-Dose Alteplase to Treat Blood Clots in Deep Leg Veins
Acute Deep Venous Thrombosis of the Lower Extremity
Primary: Number of Participants With Restored Venous Function — 28 participants
Phase 2 N=39 Raltegravir Therapy for Women With HIV and Fat Accumulation
HIV Infections · Lipodystrophy
Primary: Baseline to 24-week Change in Visceral Adipose Tissue Volume (cm^2) — -6.6; 1.8 cm^2 — p=0.52
Phase 2 N=197 Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Psoriasis
Primary: Percentage of Participants Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI 75) Score at Week 12 — 25.00; 40.82; 66.67; 2.00 percentage of…
Phase 3 N=46 Growth Retardation In Children With Special Pathological Conditions Or Disease
Endocrine System Diseases
Primary: Change From Baseline in Annual Growth Rate Standard Deviation Score (SDS) for Chronological Age (CA) at Month 36 in Intent-to-Treat (ITT) Population — -1.29; 2.36 SDS
Phase 2 N=73 Combination Chemo, Rituximab, and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma
Contiguous Stage II Adult Diffuse Large Cell Lymphoma · Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma · Stage III Adult Diffuse Large Cell Lymphoma
Primary: Progression-free Survival at 1 Year — 77 percentage of participants